 |
|
Sales & Support
Request A Quote - Email
Select Language
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Product Name: | Retatrutide LY-3437943 | Usage: | Weight Loss |
|---|---|---|---|
| MOQ: | 1 Box (10 Vials) | Package: | 4mg Or 10mg/vial, 10 Vials Per Box |
| Form: | Lyophilized Powder | Warehouse: | US, EU, CA, AU, Russia |
| CAS NO.: | 2381089-83-2 | Type: | Peptide |
Peptide Retatrutide LY-3437943 Triple Hormone Receptor Agonist for Significant Weight Reduction Results
Product desciption:
It is expected that the use of retatrutide, a triple agonist, will result in significant weight loss among individuals who are obese or overweight.
Overweight and obesity are characterized by the atypical or disproportionate buildup of fat in the body leading to notable health hazards. As per the World Health Organization (WHO), individuals cross the threshold into overweight territory when their body mass index (BMI) is more than 25 kg/m². Furthermore, a BMI surpassing 30 is indicative of obesity. Recent statistics from 2022 reveal that globally, the number of obese individuals exceeds one billion and these figures are continuously rising. The World Obesity Federation's 2023 Atlas presents alarming projections indicating that within the next 12 years, over four billion individuals, constituting 51% of the global population, will be either obese or overweight. Initially, obesity was thought to result from an imbalance between caloric intake and energy expenditure. However, current understanding recognizes that the development of obesity is influenced by complex interactions of biological and psychosocial factors. For example, various research groups have identified many genetic loci associated with weight and body dimensions. Additionally, rare genetic disorders like Prader–Willi syndrome, characterized by hyperphagia, frequently contribute to obesity. Not only do overweight and obesity lead to increased fat mass and body surface area, but it also creates an environment conducive to the development of severe diseases. These include heart diseases, diabetes mellitus, stroke, and pregnancy‐related complications.
To combat obesity, the most effective approach is weight loss. Even a modest weight reduction of 5%–10% can yield cardiovascular health benefits and lower blood sugar while >10% weight loss is associated with even greater improvement. Weight management strategies encompass various interventions, starting with dietary choices, physical exercise, and progressing toward cognitive‐behavioral techniques, pharmacological options, and, in some cases, surgical interventions.
Related products:
| GH 10iu 191AA | GH Fragment 176-191 | Adipotide |
| Melanotan II | Tirzepatide | Epithalon |
| Growth hormone | KPV | Oxytocin 2 |
| IGF1-LR3 | PT-141 | |
| Cagrilintide | P21 peptide | GHK-CU |
| HCG 5000iu | BPC-157 | Fox04 dri |
| TB-500 | CJC-1295 | DSIP |
| Hexarelin | HMG 75iu | AOD9604 |
| Ipamorelin | Sermorelin | MGF |
| Selank | Semaglutide | Peg-mgf |
| Semax | Tesamorelin | EPO 3000iu |
| Thymalin | Thymosin alpha | Follistatin 344 |
| GHRP2 | GHRP6 | Kisspeptin-10 Peptide |
| Gondorelin | IGF-1 DES | Dermorphin |
| IGF-LR3 | Melanotan | ACE-031 |
| Mots-C | Myostatin | AICAR |
| Please contact us for more products | ||
Product Photos:
Certifications:
Company:
FAQ:
Contact Person: jason
Tel: +86 17792557883
